LB Pharmaceuticals is on a mission to revive an older medication by presenting a lead drug candidate that is a modified iteration of a long-established schizophrenia treatment originally developed by Sanofi. This innovative approach is gaining traction among investors, allowing LB Pharmaceuticals to enhance its initial public offering (IPO) and raise an impressive $285 million to fund vital clinical trials.
The New York-based LB Pharmaceuticals initially set its IPO terms earlier this week, planning to offer over 16.6 million shares priced between $14 and $16 each, aiming to generate approximately $250 million at the midpoint of this pricing range. However, on late Wednesday, LB Pharmaceuticals increased the offering size to 19 million shares, set at $15 each. These shares are set to be traded on the Nasdaq under the stock symbol LBRX.
LB Pharmaceuticals’ lead drug candidate, LB-102, is based on amisulpride, a medication that was developed in the 1980s at Sanofi. While this medication received regulatory approvals in over 50 countries for treating schizophrenia, Sanofi opted not to pursue FDA approval due to the drug’s short remaining patent life, as mentioned in LB’s IPO filing.
Amisulpride, marketed under the brand name Solian by Sanofi, is an oral small molecule that functions by blocking specific dopamine receptors, particularly the D2 and D3 receptors. The side effects commonly associated with current dopamine receptor antagonists include drowsiness, weight gain, movement disorders, and alterations in heart rhythm. LB Pharmaceuticals claims that their modification of the molecule enhances its ability to penetrate the blood-brain barrier while keeping its binding capabilities to its targets largely unaffected.
LB Pharmaceuticals believes that the chemical modifications made to LB-102 allow for lower dosing compared to amisulpride. The company states in its filing, “By lowering the dosage, we aim to reduce the side effects typically associated with amisulpride. Furthermore, this alteration in chemical structure permits us to offer a different dosing frequency for LB-102 compared to amisulpride, as we are developing it for once-daily dosing instead of the conventional twice-daily regimen of amisulpride.
During Phase 2 testing, LB Pharmaceuticals reported that all three once-daily doses of its medication yielded statistically significant results when compared to a placebo, measured on a recognized scale for assessing schizophrenia symptoms. Adverse events reported included insomnia, headache, anxiety, and agitation, while LB noted that any weight gain was modest and did not demonstrate a clinically meaningful indication in metabolic parameters.
LB Pharmaceuticals is preparing to advance to a placebo-controlled Phase 3 clinical trial for LB-102, which will evaluate both low and high doses of the investigational drug. The trial aims to enroll 400 patients. Similar to the Phase 2 study, the primary objective of this six-week Phase 3 trial is to measure the change in scores from baseline using the standard scale for evaluating schizophrenia symptoms. LB Pharmaceuticals plans to initiate this study in the first quarter of 2026, with preliminary results expected in the latter half of 2027.
The FDA mandates two pivotal trials to facilitate approval for a schizophrenia medication. In its filing, LB Pharmaceuticals stated that, given the FDA feedback and historical data, the Phase 2 study, which included 359 patients, may qualify as one of the two necessary pivotal trials. If this is the case, a successful Phase 3 trial could lead to discussions with the FDA regarding a regulatory submission in early 2028. However, the FDA must first concur that the Phase 2 study meets the criteria of a pivotal trial. Furthermore, LB Pharmaceuticals believes that LB-102 may have potential applications for other indications, with a Phase 2 trial in bipolar depression slated to commence in the first quarter of 2026, and preliminary findings expected in early 2028.
LB Pharmaceuticals initially submitted its IPO plans last month, as the new funds are critically important for its operations. Earlier this spring, the company faced a cash flow crisis that led to a corporate restructuring and layoffs. By the end of June, LB Pharmaceuticals reported a cash position of merely $14.2 million. With the funds raised from the IPO, LB Pharmaceuticals intends to allocate approximately $133 million for the Phase 3 testing of LB-102, according to their filing. An additional $25 million is earmarked for progressing the drug through Phase 2 testing for bipolar depression. LB Pharmaceuticals is also working on developing a long-acting injectable formulation of LB-102, although the filing did not specify any financial allocations for these initiatives.
Stay updated on the latest developments in litigation, regulation, financial services trends, and mergers by subscribing to Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.
